Q-linea AB (publ) (STO:QLINEA)

Sweden flag Sweden · Delayed Price · Currency is SEK
24.58
+1.07 (4.57%)
At close: Feb 27, 2026
-57.91%
Market Cap 465.76M
Revenue (ttm) 19.46M
Net Income (ttm) -182.49M
Shares Out 18.95M
EPS (ttm) -27.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,642
Average Volume 6,964
Open 23.51
Previous Close 23.51
Day's Range 23.51 - 24.61
52-Week Range 20.79 - 79.00
Beta 0.77
RSI 49.60
Earnings Date Feb 6, 2026

About Q-linea AB

Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, European Union, the Middle East, and the United States. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture unit for incu... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2007
Employees 82
Stock Exchange Nasdaq Stockholm
Ticker Symbol QLINEA
Full Company Profile

Financial Performance

In 2025, Q-linea AB's revenue was 19.46 million, an increase of 370.16% compared to the previous year's 4.14 million. Losses were -182.49 million, -15.86% less than in 2024.

Financial Statements

News

Q-linea AB (FRA:3F80) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...

Q-linea AB (FRA:3F80) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Restructuring

24 days ago - GuruFocus

Q-linea AB (OSTO:QLINEA) Q3 2025 Earnings Call Highlights: Strong Demand and Strategic ...

Q-linea AB (OSTO:QLINEA) Q3 2025 Earnings Call Highlights: Strong Demand and Strategic Partnerships Amid Challenges

4 months ago - GuruFocus